# 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

> **NCT05520255** · PHASE3 · RECRUITING · sponsor: **University of Alberta** · enrollment: 2800 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-PSMA-1007

## Key facts

- **NCT ID:** NCT05520255
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-25
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 2800 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05520255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05520255, "18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05520255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*